NFlection Therapeutics Seeking Adult Participants for Clinical Trial on Cutaneous Neurofibromas (cNFs)

Author: NFlection Therapeutics

Published On: 11/18/2021

NFlection Therapeutics, Inc., a clinical-stage biopharmaceutical company, is currently recruiting adult patients for NFX-179 for the treatment of cutaneous neurofibromas. NFX-179 is a topical, first-in-class, “soft” MEK inhibitor that is currently being evaluated in Phase 2 clinical trials in patients with NF1. 

Volunteers, aged 18 years and older, are wanted for a clinical research study using an investigational topical medication. Patients must have a clinical diagnosis of NF1 and must have 10 or more cutaneous neurofibromas on their skin. During this study, all participants are seen by a board-certified dermatologist. There are no cost study-related evaluations and qualified participants will be reimbursed for time and travel. 

To learn more about NFX-179 and to find available clinic sites, visit the ClinicalTrials.gov page here. Host sites are listed at the bottom of the page under "Contacts and Locations." 

Anyone considering participating in a clinical trial should discuss the matter with his or her physician. If you or a loved one is interested in participating in NF research, please read our clinical trials brochure to learn more about the clinical trial process and what that entails.